GRPR and neoplasm: They focused on the impact of combining 44gSc and 68 Ga-labeled DOTA complexes with the GRPR antagonist BBN2 on GRPR affinity in vitro, as well as their biodistribution and tumor uptake in MCF7 and PC-3 models.